IP Library Granted Patent US 10,071,241
Granted Patent B2
US 10,071,241 · App. 15/814,817 · Granted Sep 11, 2018

Therapy delivery devices and methods for non-damaging neural tissue conduction block

Inventors: Niloy Bhadra (Cleveland Heights, OH); Kevin L. Kilgore (Avon Lake, OH); Narendra Bhadra (Chesterland, OH); Jesse Wainright (Willoughby Hills, OH); Tina Vrabec (Willoughby Hills, OH); Manfred Franke (South Euclid, OH)
Assignee: Case Western Reserve University
A61N1/0556A61N1/06A61N1/20A61N1/36064A61N1/36067A61N1/36071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,071,241
App. No.
15/814,817
Granted
Sep 11, 2018
Kind
B2
Abstract

Devices and methods for blocking signal transmission through neural tissue. One step of a method includes placing a therapy delivery device into electrical communication with the neural tissue. The therapy delivery device includes an electrode contact having a high charge capacity material. A multi-phase direct current (DC) can be applied to the neural tissue without damaging the neural tissue. The multi-phase DC includes a cathodic DC phase and anodic DC phase that collectively produce a neural block and reduce the charge delivered by the therapy delivery device. The DC delivery can be combined with high frequency alternating current (HFAC) block to produce a system that provides effective, safe, long term block without inducing an onset response.

Claims (25)

1. An electrode comprising:

at least one contact adapted to directly contact neural tissue and configured to deliver a therapy signal to the neural tissue,

wherein the at least one contact comprises a high charge capacity material that prevents formation of irreversible reaction products when the therapy signal delivers a charge of 100 μC or more to the neural tissue.

2. The electrode of claim 1 , wherein the therapy signal comprises at least one direct current (DC) with at least one polarity.

3. The electrode of claim 1 , wherein the therapy signal comprises a DC of a polarity and a high frequency alternating current (HFAC), wherein the HFAC is applied later in time than the DC.

4. The electrode of claim 1 , wherein the at least one contact has a geometric surface area of at least about 1 mm 2 .

5. The electrode of claim 4 , wherein the geometric surface area is between about 3 mm 2 and 9 mm 2 .

6. The electrode of claim 1 , wherein the at least one contact is fabricated of the high charge capacity material.

7. The electrode of claim 1 , wherein the at least one contact comprises a base body that at least partially is coated with the high charge capacity material.

8. The electrode of claim 1 , wherein the high charge capacity material is platinum black, titanium nitride, tantalum, or poly(ethylenedioxythiophene).

9. The electrode of claim 1 , further comprising a nerve cuff housing the at least one contact.

10. The electrode of claim 1 , wherein the at least one contact is monopolar.

11. A method comprising

placing at least one contact of an electrode in direct contact with neural tissue; and

delivering a therapy signal through the at least one contact to the neural tissue;

wherein the at least one contact comprises a high charge capacity material that prevents formation of irreversible reaction products when the therapy signal delivers a charge of 100 μC or more to the neural tissue.

12. The method of claim 11 , wherein the neural tissue comprises a peripheral nerve.

13. The method of claim 11 , wherein the neural tissue comprises the brain or spinal cord.

14. The method of claim 11 , wherein the neural tissue comprises a motor nerve, a sensory nerve, an autonomic nerve, or any suitable combination thereof.

15. The method of claim 11 , further comprising blocking signal transmission through at least a portion of the neural tissue based on the application of the therapy signal.

16. The method of claim 11 , wherein the therapy signal comprises a current that delivers the charge of 100 μC or more to the neural tissue.

17. The method of claim 11 , wherein the therapy signal is delivered for a time between one second and 600 seconds.

18. The method of claim 11 , wherein the therapy signal is delivered for a time between one second and 10 seconds.

19. The method of claim 11 , wherein the therapy signal is delivered for a time of 30 seconds or more.

20. The method of claim 11 , wherein the at least one contact has a geometric surface area of at least about 1 mm 2 .

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 20, 2023
From: CASE WESTERN RESERVE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064028/0702 →
Continuity (5)
Continuation 15178633 · Jun 10, 2016
Division 14408017
Provisional Application 61821862 · May 10, 2013
Provisional Application 61660383 · Jun 15, 2012
Related Publication 20180117314A1 · May 3, 2018
Cited By (5)
US 12,268,865 US 12,465,260 US 12,465,776 US 12,558,551 US 12,685,864